MPLT - CIK 0001770069
The table below shows MapLight Therapeutics, Inc.'s cash flow statement line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating cash flow | -$138.14M | -$78.81M |
| Capital expenditure | $473.00K | $770.00K |
| Investing cash flow | -$323.21M | -$80.79M |
| Dividends paid | - | - |
| Stock buybacks | - | - |
| Financing cash flow | $469.82M | $118.06M |
MapLight Therapeutics, Inc. reported operating cash flow of -$138.14M for fiscal year 2025. That is down 75.3% from -$78.81M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.